Will Worse Side Effects for Moderna's Vaccine Boost Pfizer's Fortunes?
Three COVID-19 vaccines are currently available to Americans. One of them, however, faces some challenges. Johnson & Johnson won't be able to supply as many doses of its vaccine in the next few weeks as originally hoped due to manufacturing issues at a contractor's facility. Questions about whether the vaccine could cause blood clots on a very rare basis have also arisen.
With these headwinds for J&J, the vaccines developed by Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) (with its partner BioNTech (NASDAQ: BNTX)) are in high demand. Both vaccines have very high efficacy levels. Both Moderna and Pfizer/BioNTech have secured supply deals with the U.S. for 300 million doses each.
But new research findings appear to indicate that individuals who receive Moderna's vaccine are more likely to experience reactions and side effects. Could this latest news boost Pfizer's fortunes?
Source Fool.com
